<SEC-DOCUMENT>0001193125-20-211339.txt : 20200806
<SEC-HEADER>0001193125-20-211339.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806073629
ACCESSION NUMBER:		0001193125-20-211339
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200806
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		201079849

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d26745d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;6, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39363</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMATICS N.V. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paul-Ehrlich-Stra&szlig;e 15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>72076 T&uuml;bingen, Federal Republic of Germany </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT>
<FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM <FONT STYLE="white-space:nowrap">6-K</FONT>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2020, Immatics N.V. issued a press release, a copy of which is attached hereto as Exhibit 99.1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated August&nbsp;6, 2020</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">IMMATICS N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: August&nbsp;6, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;/s/ Harpreet Singh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d26745dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g26745gr.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRESS RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immatics Extends Cell Therapy Manufacturing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration with UTHealth </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the</FONT></FONT> art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collaboration ensures continued clinical batch supply for all of Immatics&#146; ongoing and next Adoptive Cell
Therapy (ACT) clinical trials in US and Europe </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Houston, Texas, August</B><B></B><B>&nbsp;6, 2020 &#150; </B>Immatics N.V. (NASDAQ:
IMTX; &#147;Immatics&#148;), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced the extension of its cell therapy manufacturing collaboration with The
University of Texas Health Science Center at Houston (UTHealth), in Houston, Texas. The continued collaboration grants Immatics access to UTHealth&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> cGMP manufacturing infrastructure at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, enabling continued production and supply of Immatics&#146; specialized,
cell-based product candidates for testing in multiple clinical trials. Maximum capacity of the facility is anticipated at 48 ACTengine<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> T cell products per month. The new agreement will run
until the end of 2024. Under the agreement, UTHealth will provide Immatics with exclusive access to three cGMP suites and support areas for the manufacturing of various Adoptive Cell Therapy (ACT) products. Therapeutic T cell production will be
carried out by Immatics&#146; manufacturing personnel and will be supported by a UTHealth-Immatics joint quality team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steffen Walter, Ph.D., Chief
Technology Officer at Immatics, commented: &#147;During the last five years, we have established a strong and productive partnership with UTHealth that has enabled the initiation of four ongoing clinical trials. As we remain focused on the
development of our clinical pipeline, this extension of our collaboration with UTHealth will fulfill Immatics&#146; manufacturing needs for our early-stage ACT clinical programs for the next four years. Being able to rely on a partner with profound
cell therapy expertise who is familiar with our technologies and can support cGMP cell therapy production is critical to ensuring the advancement of our clinical trials. We look forward to continuing this fruitful collaboration with the experts at
UTHealth.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immatics Press Release August 6, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1&nbsp;&nbsp;|&nbsp;&nbsp;4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g26745gr.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fabio Triolo, D.d.R., M.Phil., Ph.D., The Clare A. Glassell Distinguished Chair and Director of the Cellular
Therapy Core at UTHealth, added: &#147;Signing the extended contract with Immatics fits into our strategy at UTHealth of supporting the development of new treatments for patients in need. We therefore look forward to continuing our collaboration and
further leveraging the potential of our manufacturing capabilities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immatics&#146; ACT Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACTengine<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a personalized approach in which the patient&#146;s own T cells are genetically modified
to express a novel proprietary TCR cognate to one of Immatics&#146; proprietary cancer targets which are then reinfused back into the patient. Immatics&#146; latest proprietary ACTengine<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
manufacturing processes are designed to generate cell product candidates within a short six day manufacturing window and to deliver highly proliferative T cells, with the capability to infiltrate the patient&#146;s tumor and function in a
challenging solid tumor microenvironment. The process is designed to rapidly produce younger, better-persisting T cells capable of &#147;serial&#148; killing tumor cells <I>in vitro</I>. Immatics&#146; is further advancing the ACT concept beyond
individualized manufacturing with its product class ACTallo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> which is being developed to generate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> cellular therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information on the
clinical trials can be found at the following links: <U>https://immatics.com/clinical-programs/</U> and <U>https://clinicaltrials.gov/</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ENDS - </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Editors
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immatics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics combines the discovery
of true<I> </I>targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep <FONT STYLE="white-space:nowrap">know-how</FONT> is
the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For regular updates about Immatics, visit <U>www.immatics.com</U>. You can also follow us on <U>Twitter</U> and
<U>LinkedIn</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About UTHealth </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established in 1972
by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houston&#146;s Health University and Texas&#146; resource for health care education, innovation, scientific discovery and
excellence in patient care. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immatics Press Release August 6, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2&nbsp;&nbsp;|&nbsp;&nbsp;4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g26745gr.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home
to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School and schools of biomedical informatics, biomedical sciences, dentistry and public health. UTHealth includes The University of Texas Harris County Psychiatric
Center, as well as the growing clinical practices UT Physicians, UT Dentists and UT Health Services. The university&#146;s primary teaching hospitals are Memorial Hermann-Texas Medical Center, Children&#146;s Memorial Hermann Hospital and Harris
Health Lyndon B. Johnson Hospital. For more information, <U>visit www.uth.edu</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Evelyn H. Griffin Stem Cell Therapeutics Research
Laboratory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, which is part of the Cellular Therapy Core at UTHealth, has been
Immatics&#146; manufacturing partner since 2015. The site is a U.S. Food and Drug Administration (FDA)-registered and inspected cGMP facility that has received accreditation from the Foundation for Accreditation of Cellular Therapy (FACT) as well as
certification from the Clinical Laboratory Improvement Amendment (CLIA) and the College of American Pathologists (CAP). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or
Immatics&#146; future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics&#146; focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as &#147;may&#148;, &#147;should&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;will&#148;, &#147;estimate&#148;, &#147;anticipate&#148;, &#147;believe&#148;, &#147;predict&#148;,
&#147;potential&#148; or &#147;continue&#148;, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to
differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to,
various factors beyond management&#146;s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded
as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immatics Press Release August 6, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3&nbsp;&nbsp;|&nbsp;&nbsp;4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g26745gr.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information, please contact: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>For Media Inquiries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Gretchen Schweitzer or Jacob Verghese, PhD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Graziano</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Trophic Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Solebury Trout</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Phone: +49 89 2388 7731</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone: +1 646 378 2942</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>immatics@trophic.eu</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>jgraziano@soleburytrout.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immatics N.V. </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Anja Heuer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jordan Silverstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Corporate Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Head of Strategy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Phone: +49 89 <FONT STYLE="white-space:nowrap">540415-606</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone: +1 281 810 7545</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>media@immatics.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>InvestorRelations@immatics.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>UTHealth </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Amy Laukka</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Deborah Lake</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Sr. Media Relations Specialist</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Media Relations Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Phone: +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">713-500-3053</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">713-500-3030</FONT></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Amy.Laukka@uth.tmc.edu</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Deborah.M.Lake@uth.tmc.edu</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have received this information due to your interest in Immatics (Immatics N.V. / Immatics Biotechnologies GmbH / Immatics
US, Inc.). We hope you find this information useful to update you on the developments at Immatics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics would like to continue to send you
information by Email. If you would prefer not to receive these Emails, please <I><U>unsubscribe here</U>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Immatics Press Release August 6, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4&nbsp;&nbsp;|&nbsp;&nbsp;4</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g26745gr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26745gr.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $, MP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H .GMC\,8H#;RL-W+TW#V&1
MVQGCVR*.E^BZB336CND[:=^WJ?!/[6O[0_Q1^%2Z/#\/-#T]O#FMVDI?XC26
MPUNRM]26XEA_L:U$+M9V=VJ(DOF7RRK,&9((V:&4Q?*\29MC\JH4JF$I.K2J
M.-YJ/-&-VUO%/EMI9MV?9G]&>!/A=P=QWBL?3XHS;$4\UP%2;I9+3E##U:U*
M*B_;2<OW\J<;RYU2A[EES3C<\(_:(^+_ ,3M(\ ?LW^-=&\<Z[H/B#Q5X)O;
M_P 0Q:;=I;6.I7<4.@7$%]=Z5'!]CDD:>\N<C[,J;9-FW8JJ/)SW-,PPV$RO
M%4:SH3JQC*5O@>SUOINW?RTZ(_2/"/PYX-SKB[Q*X=S;AZEFF6Y/BHQPD9U:
MD*]&_N3I0J0?M)JG"*>MVFW)_$S?_9\_;B\0:CXCT[P;\8Y=)DM-59+#3/&-
MK:1:;/!JT\\<5I!KMO8HMB+.=G$8NH(K412%=ZM$6E77*^+ZE>O[#'1I4Y-)
MQJWY.;51M9V6O,K<OW.^G)XM?1PRO)LJKY_P'4Q3GA9RE4RNI?$KZNN2,I49
MZUY3C)J7+)23@IOFBH._Z<:EJUAI&E7NL7UQ%!8:?93W]S<.X$:6]O$TSN",
M[AL7"[<[B0!DD _9XG%4L+A)XRO)4J-"'M).344HI7W>U]EZJQ_&.(KK"4JM
M6O%1AAX3E-:KE=--N+WL_=M;>^ECX!\=?M->,M:N[B#PE)'X:T-9'2UF6V@G
MUJYMPVU)KJ6Z26.Q9A@^5#'NCW &5C@U^+9WX@9CB*LJ.6.E2H0_Y>*TI=4M
M=EIKH?EV;<8YA7K*GEOLZ%&/VM)3\M]OE][(=#\3_%C2_ MQ\3X?B4;B"WUD
M:;+H&KRIJ<\ZK+#;N88+W>BW&^YBD-M"BL(6:02955J\/F7$E+(GG_\ ;O.J
M.JP]2A1BI\L^7D4E:4NUTFVU?<VP^*SFCEL\X69*52DW^YFH^^U+E:47K]R;
M['T)\(/CY:>.,Z+XD2RT?Q)#Y'E-$SI8:O'*]O;J]JLY)M[PW%Q$/LK.Q(D#
M(2 PC^RX6XUH9S25+'1I8;&1<(**FESWLD^65G?FE:ROT/H\BXIAF25+%1IT
M<0G&-E*UW)J/PO5.[VUZ'L_C7QGHO@+PWJ'B;7I_*LM/C0^1%L>[O+AW6.&S
ML8"ZF>YD<X"@\ ,[%41F7]*RC+,5FV81R_ TW*I4;=TFXPC&[G*35^51LTWT
ME[NKT/5X@SO"<.99BLSQU6-.AAX^[&4HP=2<FH4X1;U;<Y13LFU&[Z'YN>,O
MVF/B?XGN)DT[4D\)Z4TLHM[/18H#>" '$?VK4IXWGDG"]6@>V1B3A<5^^Y3X
M></X"A3GBZ=3'8N<5SJH[0B[*_+&.VO=MI=3^4L_\7^+<QJUU@L72RG!4IR5
M*E0HPK3J1N^64ZM1.2=K*T4E?4Y[PW\?_BQX9N4GB\5WNK0J<R67B%4UFWF!
M()0O*!=0CCCR;B''K@G/H8[@#AC&8:5..#^J5WM7HU7S1??V;?(_1Z?,\O+/
M%/C'+,3"I+-?K^'@]:%;#4E&2[.I%*:]4[GZ!_!CXQ67Q5T.>>6"WTKQ!I<P
MM]6TE)Q(@\P,]O?69D4.UE,B. 2&V/&\99L*[?A?%O#&(X;QWL:%>IB<)-)T
MZTZ2A=VBY0E:\5*#E96?O1L[+4_IKP]XWP_&F7.=6%+"9KAI.-;#TJO.^7FD
MX5(PE:?+**BV[-*3:OH>Y5\P?H 4 % !0 4 % !0 4 % !0 =J-OD%NFQXC^
MT1XHO_!OP5^(_B'29WM-4L/#-[%IUS$,R6U]J!BTZTND P=T,]VD@PRG]WUK
MS\TJU,-EN+K4[WBM-;;VC^MS[;PVR:GQ!Q[PQDM6*E1Q>,Y90:3C/V=/VJ33
MT:?+9IZ--KJ?BY\&?CS\0OAA,/#>BMIGB+PQX@U&VBU+P;XH@_M#1+^XO)8K
M65X"QWV%S.#&'9/,BDD'F2P2G 'Y?E&?XK#*.%C3^MPQ4H3E&H[\CJ6;47)-
MI*]K*R?5:(_T)\3O"[A'B["8G-94ZN19ODN%J3H8[!4E2J1I8;:C*-*5.52R
M2C&;<N1)\EE*5_M?]I6'X!>/?'UI\*?$^MZU\,O&O@[1=.TCPOXCCM+67X>0
M)JMC9:O9:)>Z=;W*BSB)O;2$SM!9(JHJ"XP@2OK<YCD^,Q<<MK5)8?%4H4XP
M<E^YBYQ4DM[+22_EZ:NR1_//@_/Q2X4X7GQODF7X?BOAC-\7BZ^/P,<1'#YO
M6CAIRPU:K&I6A)55_LTE&DI5IN3DXTXNI*;_ #\^*WPA\8?!_P 0#P_XKM(9
M(;J!;K2=<TUIKG0M<LF.&ETV^DAC\QT.$FMW1)4#C*".>&63XS'Y/BLKQ*IU
MYQK0FG[*I"]FXI5%H]5[L'\UZ,_JO@;Q!X8\1LOJ8K))U8O"*=/%99BJ+HU\
M&ZD*M/EG!MTZJDXMJ=.ZBDN:TII'Z/0^,?$7B[]F#X':7)=.VJ>+KJ/PW>W5
MU-@WJ^&]7O-#M?M=SCA);JQL)I'(/$+$CGCT>),PQ&)X6R3!TI\M7-I0P[<I
M-15JJI-S?\MHMOR/\M/I)96\B\0.).'\"XTZ.+S"A52C:G""QU+#8Q4FHZ)+
MZPH/IUM;0N:'^SS-IWC?0M%\;^(/"?\ 9UZ7F_LZSUV:#6=7$<-RXL]/LY[2
M"<HTMN5DE4I^[60(VXUY&$X(K4<VPM+,\;@HT53YHTHRO*?OI/3E2T6EV?B>
M#X1CA\TI4<=BL-.$Z?,J497G\=MG'Y7/4?CUX!^'^B>%_"CRW-WX7T[1=3O+
M.PT_0--MM1EO#JR-/=F"WN[^TCANA)91R&\>9F5"T9'[T;?HN+\FR/#X7!NK
M6>#H86:E[&$&U.*E%_#%QCKYK]#V>)<LRC"X#"^UG+"4*$TE&,;\R4UT4HIW
MLM7TMY'@WQ)UKX2IIOA"X^&%O>6>OZ28)KVX^S7%G+%#;1K-$=4DN-R7.K+>
MK')YL+2<>81(P*A?C>(,;P[".45<BO'$8=.5;E@Z;NO9N%VDKOFA+:]CYO-,
M5D?+E]7+XSIU*,&I-0Y'+DY)1DVFKMMO7H;W[4GBN77;/X6Q*'@MM0\+_P#"
M32V[9(%WJL=HL(^;GS(8H;M >.)V'.ZO[9\%%];R6OF\U'GQ='#)7^).<(UI
M6=KKXG?77J?F_C1FD\12X5PM&4U2JX/ZU65VH^^H<MU?6TK6O>Q\BU^UGX.%
M 'I/PE\:OX \<:;XA19)(D@U&RO+>)BOVFTN;"XQ$X .=M\EC,/3R3_>)KYW
MB;)*&=Y;/#2DJ=:$Z<HRY4VDY+;;=0MOLSZO@WB;$\+9L\=0YN2=.4)*,G'7
MELKVWTD?L=7\LG]YA0 4 % !0 4 % !0 4 % "'H>W'TQ0M+>0FM&MM#S7XL
M>"O^%B?#GQEX*2X2TF\0Z'>:=9WDJ[X[2_9%DTZ[=/XXX;Z.&1E[A"._//C:
M/M\%7P[5W45DOG=?C8^AX.XAJ<)\4Y#Q+1;7]D8CV\O2WLI)*ZW@I:)K5W;5
MS^=R.*]\(^*$AU:TEL=1\+:\B:E8SH4FM;S1=1 NK:1#DY2>V=.X.."01G\5
MI0G@<QITI4N3ZM649-K[,&XI-]4FE;IV/]9,1C</Q%P]/%9/6ABL'G&7UJE"
MI&7.W"O@ZDU%RE[R34HODDE:2B[<R1],_MMZ?+;?'O5M5*L;;Q-X9\)Z[I\H
M5C'-9+HD.C>9"^"'3S=&N<[>F#D<\^[Q=&5+-XXB-O9XF-&HI+;1>SW7_7L_
M'OHV8E5_#>AE<X<L\GS+-<"U)>]'$2K_ %OEDGJG_M<;76UM3H?@/JZ_'/PC
MJG[-WC>[@GDTW2+K7_@WK4[;=0T'7=%BF!T!;H9\[33832R1Q.I"VUO<Q#:J
M6ZQ]&4XI9O1Q.4XI.551Y\/5?\2%1-I\M1ZQO"4HNVK@Y)W6AXGB9E=3PKSW
M*O%OA#!O!86MB(Y?Q'@:<6L)/"8BFH1KRPL.2*E"M3IVJ+F2JRIM).<Y2^S_
M !!\%=3\+_LS>!?#>Z.;7_AM8)K&LQ6Q:>.::]:ZO/%$=K(H&8[>]U*:Z$@
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M_AEP<N+,VQ/M:-3^S<)32JR>D/;S53E2<U;X(4VTE:[O>[/U@K^<#^TPH *
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M^O1:[J.ZSU35[FTM?.U:&.X/V:WAPRX7:A*DV#8^AE_U8[<#IQC!XX'TH \
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$;R/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
